Stocks · News reference
DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $12.
Read original at benzingaTD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.
Read original at benzingaDarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.22) by 40.98 percent. This is a 82.44 percent increase over losses of $(4.10) per share from the
Read original at benzinga